Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Aug;59(8):1899-905.
doi: 10.2337/db10-0308. Epub 2010 Jun 3.

Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women

Marleen Kars  1 , Ling Yang, Margaret F Gregor, B Selma Mohammed, Terri A Pietka, Brian N Finck, Bruce W Patterson, Jay D Horton, Bettina Mittendorfer, Gökhan S Hotamisligil, Samuel Klein
Affiliations
Randomized Controlled Trial

Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women

Marleen Kars et al. Diabetes. 2010 Aug.

Abstract

Objective: Insulin resistance is commonly associated with obesity. Studies conducted in obese mouse models found that endoplasmic reticulum (ER) stress contributes to insulin resistance, and treatment with tauroursodeoxycholic acid (TUDCA), a bile acid derivative that acts as a chemical chaperone to enhance protein folding and ameliorate ER stress, increases insulin sensitivity. The purpose of this study was to determine the effect of TUDCA therapy on multiorgan insulin action and metabolic factors associated with insulin resistance in obese men and women.

Research design and methods: Twenty obese subjects ([means +/- SD] aged 48 +/- 11 years, BMI 37 +/- 4 kg/m2) were randomized to 4 weeks of treatment with TUDCA (1,750 mg/day) or placebo. A two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labeled tracer infusions and muscle and adipose tissue biopsies were used to evaluate in vivo insulin sensitivity, cellular factors involved in insulin signaling, and cellular markers of ER stress. RESULTS Hepatic and muscle insulin sensitivity increased by approximately 30% (P < 0.05) after treatment with TUDCA but did not change after placebo therapy. In addition, therapy with TUDCA, but not placebo, increased muscle insulin signaling (phosphorylated insulin receptor substrate(Tyr) and Akt(Ser473) levels) (P < 0.05). Markers of ER stress in muscle or adipose tissue did not change after treatment with either TUDCA or placebo.

Conclusions: These data demonstrate that TUDCA might be an effective pharmacological approach for treating insulin resistance. Additional studies are needed to evaluate the target cells and mechanisms responsible for this effect.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Liver, muscle, and adipose tissue insulin sensitivity before (□) and after (formula image) 4 weeks of placebo or TUDCA treatment. A: Hepatic insulin sensitivity index. B: Glucose rate of disappearance (Rd); data represent only 8 of 10 subjects who received TUDCA treatment because of technical difficulties in obtaining blood samples in two subjects. C: Palmitate rate of appearance. Values are means ± SD. *Value significantly different from corresponding value before treatment, P < 0.05. †Main effect of insulin, P < 0.0001.
FIG. 2.
FIG. 2.
Effect of placebo (□) or TUDCA (formula image) treatment on skeletal muscle IRSTyr, AktSer473, and JNKThr183/Tyr185 levels. Values are means ± SD and expressed relative to values before treatment, which were set to one for each person. *Value significantly different from corresponding placebo value, P < 0.05.
FIG. 3.
FIG. 3.
Endoplasmic reticulum stress markers before (□) and after (formula image) placebo or TUDCA therapy. A: Gene expression (relative to 18S rRNA). B: Protein content (relative to actin). Values are medians and quartiles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923 - PubMed
    1. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145–1151 - PubMed
    1. Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121 - PubMed
    1. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G: Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997;100:1166–1173 - PMC - PubMed
    1. Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A: Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res 2008;39:803–808 - PubMed

Publication types

MeSH terms